Literature DB >> 31246134

Phenotypic heterogeneity associated with germline GATA2 haploinsufficiency: a comprehensive kindred study.

Candace L Haddox1, Ryan M Carr2, Roshini S Abraham3,4, Juliana Perez Botero2, Vilmarie Rodriguez5, Animesh Pardanani2, Mrinal M Patnaik2.   

Abstract

Entities:  

Year:  2019        PMID： 31246134      PMCID： PMC6923578          DOI： 10.1080/10428194.2019.1633630

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  16 in total

1.  MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations.

Authors:  Lisa J McReynolds; Yanqin Yang; Hong Yuen Wong; Jingrong Tang; Yubo Zhang; Matthew P Mulé; Janine Daub; Cindy Palmer; Ladan Foruraghi; Qingguo Liu; Jun Zhu; Weixin Wang; Robert R West; Marielle E Yohe; Amy P Hsu; Dennis D Hickstein; Danielle M Townsley; Steven M Holland; Katherine R Calvo; Christopher S Hourigan
Journal:  Leuk Res       Date:  2018-12-04       Impact factor: 3.156

Review 2.  The role of the GATA2 transcription factor in normal and malignant hematopoiesis.

Authors:  Carmen Vicente; Ana Conchillo; María A García-Sánchez; María D Odero
Journal:  Crit Rev Oncol Hematol       Date:  2011-05-24       Impact factor: 6.312

3.  GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies.

Authors:  Xinan Wang; Hideki Muramatsu; Yusuke Okuno; Hirotoshi Sakaguchi; Kenichi Yoshida; Nozomu Kawashima; Yinyan Xu; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Shoji Saito; Yozo Nakazawa; Taro Masunari; Tadashi Hirose; Shaimaa Elmahdi; Atsushi Narita; Sayoko Doisaki; Olfat Ismael; Hideki Makishima; Asahito Hama; Satoru Miyano; Yoshiyuki Takahashi; Seishi Ogawa; Seiji Kojima
Journal:  Haematologica       Date:  2015-05-28       Impact factor: 9.941

4.  Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome.

Authors:  Amy P Hsu; Elizabeth P Sampaio; Javed Khan; Katherine R Calvo; Jacob E Lemieux; Smita Y Patel; David M Frucht; Donald C Vinh; Roger D Auth; Alexandra F Freeman; Kenneth N Olivier; Gulbu Uzel; Christa S Zerbe; Christine Spalding; Stefania Pittaluga; Mark Raffeld; Douglas B Kuhns; Li Ding; Michelle L Paulson; Beatriz E Marciano; Juan C Gea-Banacloche; Jordan S Orange; Jennifer Cuellar-Rodriguez; Dennis D Hickstein; Steven M Holland
Journal:  Blood       Date:  2011-06-13       Impact factor: 22.113

5.  Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.

Authors:  F Theis; A Corbacioglu; V I Gaidzik; P Paschka; D Weber; L Bullinger; M Heuser; A Ganser; F Thol; B Schlegelberger; G Göhring; C-H Köhne; U Germing; P Brossart; H-A Horst; D Haase; K Götze; M Ringhoffer; W Fiedler; D Nachbaur; T Kindler; G Held; M Lübbert; M Wattad; H R Salih; J Krauter; H Döhner; R F Schlenk; K Döhner
Journal:  Leukemia       Date:  2016-07-04       Impact factor: 11.528

6.  Epigenetic regulation of GATA2 and its impact on normal karyotype acute myeloid leukemia.

Authors:  M Celton; A Forest; G Gosse; S Lemieux; J Hebert; G Sauvageau; B T Wilhelm
Journal:  Leukemia       Date:  2014-02-11       Impact factor: 11.528

7.  Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents.

Authors:  Marcin W Wlodarski; Shinsuke Hirabayashi; Victor Pastor; Jan Starý; Henrik Hasle; Riccardo Masetti; Michael Dworzak; Markus Schmugge; Marry van den Heuvel-Eibrink; Marek Ussowicz; Barbara De Moerloose; Albert Catala; Owen P Smith; Petr Sedlacek; Arjan C Lankester; Marco Zecca; Victoria Bordon; Susanne Matthes-Martin; Jonas Abrahamsson; Jörn Sven Kühl; Karl-Walter Sykora; Michael H Albert; Bartlomiej Przychodzien; Jaroslaw P Maciejewski; Stephan Schwarz; Gudrun Göhring; Brigitte Schlegelberger; Annámaria Cseh; Peter Noellke; Ayami Yoshimi; Franco Locatelli; Irith Baumann; Brigitte Strahm; Charlotte M Niemeyer
Journal:  Blood       Date:  2015-12-23       Impact factor: 22.113

8.  Human leukemia mutations corrupt but do not abrogate GATA-2 function.

Authors:  Koichi R Katsumura; Charu Mehta; Kyle J Hewitt; Alexandra A Soukup; Isabela Fraga de Andrade; Erik A Ranheim; Kirby D Johnson; Emery H Bresnick
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-09       Impact factor: 11.205

9.  Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia.

Authors:  Su-Jiang Zhang; Li-Yuan Ma; Qiu-Hua Huang; Guo Li; Bai-Wei Gu; Xiao-Dong Gao; Jing-Yi Shi; Yue-Ying Wang; Li Gao; Xun Cai; Rui-Bao Ren; Jiang Zhu; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-04       Impact factor: 11.205

10.  Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Christopher N Hahn; Chan-Eng Chong; Catherine L Carmichael; Ella J Wilkins; Peter J Brautigan; Xiao-Chun Li; Milena Babic; Ming Lin; Amandine Carmagnac; Young K Lee; Chung H Kok; Lucia Gagliardi; Kathryn L Friend; Paul G Ekert; Carolyn M Butcher; Anna L Brown; Ian D Lewis; L Bik To; Andrew E Timms; Jan Storek; Sarah Moore; Meryl Altree; Robert Escher; Peter G Bardy; Graeme K Suthers; Richard J D'Andrea; Marshall S Horwitz; Hamish S Scott
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330
View more
  1 in total

1.  ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome.

Authors:  Robert R West; Katherine R Calvo; Lisa J Embree; Weixin Wang; Laura M Tuschong; Thomas R Bauer; Desiree Tillo; Justin Lack; Stephenie Droll; Amy P Hsu; Steven M Holland; Dennis D Hickstein
Journal:  Blood Adv       Date:  2022-02-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.